Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial Article

ESI Most Cited Paper Industry Collaboration International Collaboration

cited authors

  • Reck, Martin; Mok, Tony S. K.; Nishio, Makoto; Jotte, Robert M.; Cappuzzo, Federico; Orlandi, Francisco; Stroyakovskiy, Daniil; Nogami, Naoyuki; Rodriguez-Abreu, Delvys; Moro-Sibilot, Denis; Thomas, Christian A.; Barlesi, Fabrice; Finley, Gene; Lee, Anthony; Coleman, Shelley; Deng, Yu; Kowanetz, Marcin; Shankar, Geetha; Lin, Wei; Socinski, Mark A.; IMpower150 Study Grp

authors

Publication Date

  • May 1, 2019

webpage

published in

category

start page

  • 387

end page

  • 401

volume

  • 7

issue

  • 5